YouTube

La demanda sobre la «seguridad» de la píldora abortiva: actualización del caso mifepristona

Título original: The abortion pill "safety" lawsuit continues to be bullsh*t

9 oct 202311:49
MMama Doctor Joneshttps://www.youtube.com/watch?v=hhbDwhKNquYDatos de la fuente
Sobre este vídeoTraducido por IAIdioma original: English

Esta actualización trata la impugnación legal sobre la seguridad de la mifepristona, un medicamento utilizado para el aborto. El presentador sostiene que personas sin formación médica no deberían evaluar la seguridad de este fármaco, que describe como ampliamente probado. El video también enlaza documentos judiciales, cobertura periodística y fuentes médicas y de investigación sobre la seguridad y la regulación del medicamento.

En este vídeo
  • Actualización sobre la impugnación legal de la seguridad de la mifepristona
  • La opinión del presentador sobre el historial de seguridad del medicamento
  • Enlaces a documentos judiciales, noticias y fuentes médicas
Califica esta descripción
Descripción de Mama Doctor Jones

The mifepristone (abortion medication) legal case continues to be asinine propaganda bullsh*t. It was propaganda nonsense when it was originally filed and it still is, because in what world should a bunch of non-medical experts be allowed to review the safety of a medication that’s been proven TIME AND TIME AGAIN to be EXTREMELY SAFE?! Safer than literal Tylenol. It makes me so angry and the only way to vent that anger is to tell you all about it, so here it is: an update on the mifepristone lawsuit. Watch next: First Mifepristone Case Video: https://youtu.be/0iVEHcS_kGs?si=mnuxgx-WGL5U68ii Emergency Contraception: https://youtu.be/nj4N92c6Uxo?si=USv0fbbDfBtk5J2I What Your Doctor Needs You To Know About Abortion Pills: https://youtu.be/q6NHEukAnNI?si=jd2sLg47pVwpQbA3 References: MSNBC mifepristone update: https://youtu.be/ESTLS4pTkGs?si=s5caqE2CTdGSibfo Filing: https://www.law360.com/cases/6377d1beb6593203c70c9b44 Washington Post - overview of the TX case: https://www.washingtonpost.com/national-security/2023/03/15/texas-judge-abortion-pill-mifepristone-fda/ NYTimes - additional coverage of the TX case: https://www.nytimes.com/2023/03/15/health/abortion-pills-texas-lawsuit.html AG vs FDA to Remove REMS Restrictions: https://agportal-s3bucket.s3.amazonaws.com/uploadedfiles/Another/News/Press_Releases/Mifepristone%20Complaint.pdf ACOG Push Back to ADF: https://www.acog.org/news/news-releases/2023/02/acog-leads-amicus-brief-calling-mifepristone-conclusively-safe-and-effective ACOG REMS Input: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2023/01/updated-mifepristone-rems-requirements 2017 NEJM Article for Removal from REMS: https://sci-hub.se/10.1056/NEJMsb1612526 Mifepristone Safety Overview from ANSIRH: https://www.ansirh.org/sites/default/files/2022-11/mifepristone_safety_11-15-22_Updated_0.pdf Mifepristone Post-Marketing Data: https://www.fda.gov/media/154941/download Comparative Safety Legal Abortion vs Pregnancy: https://journals.lww.com/greenjournal/Abstract/2012/02000/The_Comparative_Safety_of_Legal_Induced_Abortion.3.aspx Comstock Application (DOJ Slip Opinion): https://www.justice.gov/olc/opinion/file/1560596/download NBC - Judge Kacsmaryk seems sympathetic to anti-choice arguments: https://www.nbcnews.com/news/us-news/abortion-pill-case-texas-judge-appears-sympathetic-challenge-rcna75069 New York Times - Wyoming governor signs ban on abortion pills: https://www.nytimes.com/2023/03/17/us/wyoming-abortion-pills-ban.html 12 States Challenge Restrictions on Mifepristone: https://www.reuters.com/legal/democratic-led-us-states-sue-challenge-federal-restrictions-abortion-pill-2023-02-24/ JAMA Viagra: https://jamanetwork.com/journals/jama/article-abstract/1843222 SPLC Categorizes ADF as Extremist Hate Group: https://www.splcenter.org/fighting-hate/extremist-files/group/alliance-defending-freedom Alliance Defending Freedom info: ADF Adoption Case: https://www.nytimes.com/2022/01/22/us/tennessee-jewish-couple-adopt

Comentarios

Aún no hay comentarios. ¡Sé el primero en escribir uno!